JF SmartInvest Holdings Ltd Adjusted Profit Leaps 191.8% to RMB1.02 Billion ‘Technology + Investment Research’ Dual-Driver Strategy Delivers Remarkable Results, Overseas Expansion Ushers in a New Chapter of Globalisation

HIGHLIGHTS: – Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period. – Total revenue was approximately RMB3,430.1 million, representing an increase of approxima […]

How to Choose the Right Savings Account for Your Money Goals in Singapore

SINGAPORE, Mar 27, 2026 – (ACN Newswire via SeaPRwire.com) – Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking t […]

Hua Medicine Announces 2025 Annual Results

– Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation. – Delivered record financi […]

Dynasty Fine Wines Announces 2025 Annual Results

Financial Highlights (Audited) (HKD Thousand) Year ended31 December 2025 2024 Revenue 170,011 271,372 Gross Profit 53,382 104,720 Profit Attributable to Owners of the Company 13,688 33,440 Basic Earnings per Share (HK cents) 0.97 2.37 HONG KONG, Mar 26, 2026 – (ACN Newswire via SeaPRwire.com) […]

HKTDC’s response to Hong Kong’s export figures for February

HONG KONG, Mar 26, 2026 – (ACN Newswire via SeaPRwire.com) – The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the […]

Sino Biopharm (1177.HK) Announces 2025 Annual Results

Development Highlights – During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa […]